Table 4. Multivariate analysis of variables associated with the occurrence of HCC in patients who underwent Gd-EOB-DTPA-enhanced MRI before DAA treatment.
| n=118 | Multivariate analysis | ||
|---|---|---|---|
| Variable | HR (95% CI) | p value | |
| FIB-4 index | ≤ 4.0 | 1 | |
| > 4.0 | 3.20 (0.34–29.8) | 0.31 | |
| Post-AFP (ng/mL) | ≤ 4.0 | 1 | |
| > 4.0 | 2.32 (0.60–9.01) | 0.22 | |
| Post-M2BPGi (COI) | ≤ 1.6 | 1 | |
| > 1.6 | 0.63 (0.15–2.69) | 0.53 | |
| Non-hypervascular hypo-intense nodule | negative | 1 | |
| positive | 32.4 (3.92–268) | 0.001 | |
AFP: α-fetoprotein; M2BPGi: Mac-2 binding protein glycosylation isomer; HR: hazard ratio; CI: confidence interval; Gd-EOB-DTPA: gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; MRI: magnetic resonance imaging; DAA: direct-acting antiviral.